The Chinese Market for Cancer Intervention

June 2017 | 130 pages | ID: C02EF662DB2EN
BCC Research

Abstracts

The Chinese cancer intervention market reached nearly $41.1 billion in 2016. This market should reach $46.7 billion in 2017 and $89.3 billion by 2022, at a compound annual growth rate (CAGR) of 13.8% through 2022.

Cancer treatment services as a segment should reach nearly $43.9 billion in 2017 and $83.6 billion by 2022, at a CAGR of 13.8% through 2022.

Diagnosis and detection services as a segment should reach nearly $2.9 billion in 2017 and $5.8 billion by 2022, at a CAGR of 15.0% through 2022.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

Largest Segments in the Chinese Cancer Intervention Market
Fastest Growing Segments in the Chinese Cancer Intervention Market

CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND

Market Background
Number of Cancer Cases in China
Geographical Distribution
Medical System
Drug Distribution System in China
Drug Makers
Foreign Drug Makers
Government Relationship
First- and Second-Tier Cities
Sales Channels
Homegrown Drug Makers
Government Relationship
Third- and Fourth-Tier Cities
Sales Channels
Drug Retailers
Exclusive Distributors
Hospitals
Retailers
End Consumers
Key Trends in the Chinese Cancer Intervention Market
Technology Background
Key Technology Trends in the Chinese Cancer Intervention Market

CHAPTER 4 MARKET BREAKDOWN BY TECHNOLOGY TYPE

Antitumor Drugs
Immunopotentiators
Immunosuppressors
Adjuvant Drugs
Cancer Surgery
Radiotherapy
Diagnosis and Detection

CHAPTER 5 MARKET BREAKDOWN BY PRODUCT

CHAPTER 6 MARKET BREAKDOWN BY END USE

Chinese Lung Cancer Intervention Market

CHAPTER 7 MARKET BREAKDOWN BY REGION

CHAPTER 8 ANALYSIS OF MARKET OPPORTUNITIES

CHAPTER 9 COMPANY PROFILES

CHAPTER 10 APPENDIX: GLOSSARY

Drugs used for Cancer Treatment in China
Antitumor Drugs and Immunomodulators
Chinese Antitumor Drug and Immunomodulator Market by Product Type
The Chinese Antitumor Drug Market by Product
Paclitaxel
Pemetrexed Disodium
Docetaxel
Tegafur/gimeracil/oteracil
Oxaliplatin
Imatinib
Capecitabine
Rituximab
Trastuzumab
Other Antitumor Drugs
The immunomodulator Market by Product
Thymopentin
Tacrolimus
Chinese Antitumor Drug and Immunomodulator Market by Product
Chinese Antitumor Drug and Immunomodulator Market by Sales Channel
Hospital Channel for Antitumor Drugs and Immunomodulators
Antitumor Drugs and Immunomodulators in the Chinese Drug Market
Antitumor Drugs and Immunomodulators in the Chinese Hospital Drug Market
Antitumor Drugs and Immunomodulators in the Chinese Retail Drug Market
Adjuvant Drugs
Cancer Surgery
Radiotherapy
Diagnosis and Detection
Chinese Lung Cancer Drug Market
Chinese Lung Cancer Surgery Market
Chinese Lung Cancer Radiotherapy Market
Chinese Lung Cancer Diagnosis and Detection Market
Chinese Gastric Cancer Intervention Market
Chinese Gastric Cancer Drug Market
Chinese Gastric Cancer Surgery Market
Chinese Gastric Cancer Radiotherapy Market
Chinese Gastric Cancer Diagnosis and Detection Market
Chinese Liver Cancer Intervention Market
Chinese Liver Cancer Drug Market
Chinese Liver Cancer Surgery Market
Chinese Liver Cancer Radiotherapy Market
Chinese Liver Cancer Diagnosis and Detection Market
Chinese Esophageal Cancer Intervention Market
Chinese Esophageal Cancer Drug Market
Chinese Esophageal Cancer Radiotherapy Market
Chinese Colorectal Cancer Intervention Market
Chinese Colorectal Cancer Drug Market
Chinese Breast Cancer Intervention Market
Chinese Breast Cancer Drug Market
Market of Other Cancer Types in China
Thyroid Cancer Drug Permission in China
Leukemia Drug Permission in China
Pancreatic Cancer Drug Permission in China
Lymphoma Drug Permission in China
Ovarian, Cervical and Fallopian Tube Drug Permission in China
Melanoma Drug Permission in China
East China Cancer Intervention Market
Middle China Cancer Intervention Market
North China Cancer Intervention Market
Southwest China Cancer Intervention Market
Northwest China Cancer Intervention Market
Northeast China Cancer Intervention Market
South China Cancer Intervention Market
Reference Listed Drugs
Generic Drugs
Surgery Materials
Radiotherapy Equipment
DNA Sequencing
Traditional Chinese Drugs
ACCURAGEN
ACCURAY
ANNOROAD GENE TECHNOLOGY
ASTELLAS
ASTRAZENECA
BAYER CHINA LTD.
BEIJING GENETRON HEALTH CO. LTD.
BEIJING GENOMICS INSTITUTE
BEIJING IPE CENTER
BEIJING SANVALLEY TECHNOLOGY CO. LTD.
BEIJING SCIECURE PHARMACEUTICAL CO. LTD.
BEIJING SINOMDGENE TECHNOLOGY CO. LTD.
BEIJING SOLOMENBROTHERS MEDICAL TECHNOLOGY CO. LTD.
BRISTOL-MYERS SQUIBB (CHINA) INVESTMENT CO. LTD.
CHANGBAISHAN PHARMACEUTICAL CO. LTD. (CHANGBAISHAN)
CHIATAI TIANQING PHARMACEUTICAL GROUP CO. LTD.
CSPC PHARMACEUTICAL GROUP LTD.
ELEKTA INSTRUMENT AB STOCKHOLM
FSENS
GUANGZHOU AIC BIOTECHNOLOGIES LTD
GUANGZHOU ANCHORDX LLC
GUANGZHOU EZLIFE BIO INC.
GUANGZHOU FOREVER GEN BIO-TECHNOLOGY LTD.
GUIZHOU YIBAI PHARMACEUTICAL CO. LTD. (YIBAI)
GUODA DRUGSTORE
HAINAN ZHONGHE PHARMACEUTICAL CO. LTD.
HANSOH
HITACHI MEDICAL
HUADONG MEDICINE CO. LTD.
HUAPONT LIFE SCIENCES CO. LTD.
HYBIO PHARMACEUTICAL CO. LTD.
JIANGSU HENGRUI MEDICINE CO. LTD. (HENGRUI)
JOHNSON & JOHNSON
LIVZON PHARMACEUTICAL GROUP CO. LTD. (LIVZON)
LUNAN PHARMACEUTICAL GROUP
LUYE PHARMA GROUP (LUYE)
MASEP INFINI MEDICAL SCIENCE TECHNOLOGY CO. LTD.
MSD CHINA
NOVARTIS
PFIZER CHINA
QILU PHARMACEUTICAL CO. LTD.
ROCHE CHINA
SANOFI
SCICLONE PHARMACEUTICALS INC.
SHANGHAI BIOASIA GENE CO. LTD.
SHENZHEN HAPLOX BIOTECHNOLOGY CO. LTD.
SHENZHEN YUCEBIO CO. LTD.
SINOPHARM A-THINK PHARMACEUTICAL CO. LTD. (A-THINK)
SINOPHARM CHUANKANG PHARMACEUTICAL CO. LTD. (CHUANKANG)
SL PHARM
TAIHO PHARMA
VARIAN MEDICAL SYSTEMS INC.
WUHAN HUALONG BIO-CHEMICAL PHARMACEUTICAL CO. LTD.
YATAI PHARMACEUTICALS
ZHEJIANG JIUXU PHARMACEUTICAL CO. LTD. (JIUXU)
ZHEJIANG KANGLAITE PHARMACEUTICAL CO. LTD. (KANGLAITE)

ZHENDONG GROUP

List Of Tables

LIST OF TABLES

Summary Table Chinese Market for Cancer Intervention, by Service Type, Through 2022
Table 1 Cancer Cases and Shares in China, by Indication, in 2015
Table 2 Cancer Cases and Rates in China, by Indication, in 2015
Table 3 Number of Hospitals in China, by Type, 2014 and 2015
Table 4 Number of City and County Hospitals in China, by Grade, 2014 and 2015
Table 5 Number of City and County Hospitals in China, by Ownership, 2014 and 2015
Table 6 Numbers of Town and Village Hospitals in China, by Type, 2014 and 2015
Table 7 Key Market Trends for the Cancer Intervention Market in China
Table 8 Key Technology Trends for Cancer Intervention in China
Table 9 Chinese Market for Cancer Intervention, by Major Segments, Through 2022
Table 10 Chinese Antitumor Drug Market, by Technology Type, Through 2022
Table 11 Chinese Immunopotentiator Market, by Technology Type, Through 2022
Table 12 Chinese Immunosuppressor Market, by Technology Type, Through 2022
Table 13 Chinese Adjuvant Drug Market, by Technology Type, Through 2022
Table 14 Chinese Cancer Surgery Market, by Surgery Purpose, Through 2022
Table 15 Chinese Radiotherapy Market, by Technology Type, Through 2022
Table 16 Chinese Cancer Diagnosis and Detection Market, by Technology Type, Through 2022
Table 17 Chinese Market for Cancer Intervention, by Major Type, Through 2022
Table 18 Chinese Market for Cancer Treatment, by Major Purpose, Through 2022
Table 19 Drugs for Cancer Treatment in China, by Product Type, Through 2022
Table 20 Chinese Antitumor Drug and Immunomodulators Market, by Product Type, Through 2022
Table 21 Chinese Antitumor Drug Market, by Product, Through 2022
Table 22 Chinese Paclitaxel Market, by Product, Through 2022
Table 23 Chinese Paclitaxel Market Share, by Product, in 2016
Table 24 Chinese Pemetrexed Disodium Market, by Producer, Through 2022
Table 25 Chinese Pemetrexed Disodium Market Share, by Producer, in 2016
Table 26 Chinese Docetaxel Market, by Producer, Through 2022
Table 27 Chinese Docetaxel Market Share, by Producer, in 2016
Table 28 Chinese Tegafur/Gimeracil/Oteracil Market, by Producer, Through 2022
Table 29 Chinese Tegafur/Gimeracil/Oteracil Market Share, by Producer, in 2016
Table 30 Chinese Oxaliplatin Market, by Producer, Through 2022
Table 31 Chinese Oxaliplatin Market, by Producer, in 2016
Table 32 Chinese Imatinib Market, by Producer, Through 2022
Table 33 Chinese Imatinib Market Share, by Producer, in 2016
Table 34 Chinese Capecitabine Market, by Producer, Through 2022
Table 35 Chinese Capecitabine Market Share, by Producer, in 2016
Table 36 Chinese Rituximab Market, by Producer, Through 2022
Table 37 Chinese Trastuzumab Market, by Producer, Through 2022
Table 38 Chinese Immunomodulator Market, by Product, Through 2022
Table 39 Chinese Thymopentin Market, by Producer, Through 2022
Table 40 Chinese Thymopentin Market Share, by Producer, 2016
Table 41 Chinese Tacrolimus Market, by Producer, Through 2022
Table 42 Chinese Tacrolimus Market Share, by Producer, in 2016
Table 43 Chinese Antitumor Drug and Immunomodulator Market, by Product, Through 2022
Table 44 Chinese Chemical and Biological Antitumor Drug and Immunomodulator Market, by Product, Through 2022
Table 45 Traditional Chinese Antitumor Drug and Immunomodulator Market, by Product, Through 2022
Table 46 Chinese Antitumor Drug and Immunomodulator Market, by Sales Channel, Through 2022
Table 47 Chinese Hospital Antitumor Drug and Immunomodulator Market, by Hospital Type, Through 2022
Table 48 Chinese Chemical & Biological Antitumor Drug and Immunomodulator Market, by Hospital Type, Through 2022
Table 49 Traditional Chinese Antitumor Drug and Immunomodulator Market, by Hospital Type, Through 2022
Table 50 Chemical and Biological Drug Market in Hospitals in China, by Drug Type and Hospital Type, 2016
Table 51 Traditional Chinese Drug Market in Hospitals in China, by Drug Type and Hospital Type, in 2016
Table 52 Chinese Retail Drug Market, by Drug Type, Through 2022
Table 53 Chinese Adjuvant Drug Market, by Product Type, Through 2022
Table 54 Chinese Antiemetic Drug Market, by Product Type, Through 2022
Table 55 Chinese Cancer Surgery Market, by Product and Service Type, Through 2022
Table 56 Chinese Radiotherapy Market, by Service Type, Through 2022
Table 57 Chinese Radiotherapy Equipment Market, by Service Type, Through 2022
Table 58 Chinese Cancer Diagnosis and Detection Market, by Service Type, Through 2022
Table 59 Chinese Cancer DNA Sequencing Diagnosis and Detection Market, by Indication, Through 2022
Table 60 Chinese Cancer DNA Sequencing Diagnosis and Detection Market, by Test Purpose, Through 2022
Table 61 Chinese Cancer DNA Sequencing Diagnosis and Detection Market, by Test Complexity, Through 2022
Table 62 Chinese Cancer Intervention Market, by Cancer Type, Through 2022
Table 63 Chinese Lung Cancer Intervention Market, by Service Type, Through 2022
Table 64 Chinese Lung Cancer Intervention Market Comparison, by Service Type, 2016
Table 65 Chinese Lung Cancer Drug Market, by Product, Through 2022
Table 66 Tinibs for Lung Cancer Intervention in China, by Drug, 2016
Table 67 Lung Cancer Targeting Drug Permission in China, 2016
Table 68 Chinese Gastric Cancer Intervention Market, by Service Type, Through 2022
Table 69 Chinese Gastric Cancer Intervention Market Comparison, by Service Type, 2016
Table 70 Chinese Liver Cancer Intervention Market, by Service Type, Through 2022
Table 71 Chinese Liver Cancer Intervention Market Comparison, by Service Type, 2016
Table 72 Chinese Esophageal Cancer Intervention Market, by Service Type, Through 2022
Table 73 Chinese Esophageal Cancer Intervention Market Comparison, by Service Type, 2016
Table 74 Chinese Colorectal Cancer Intervention Market, by Service Type, Through 2022
Table 75 Chinese Colorectal Cancer Intervention Market Comparison, by Service Type, 2016
Table 76 Colorectal Cancer Targeting Drug Permission in China, 2016
Table 77 Chinese Breast Cancer Intervention Market, by Service Type, Through 2022
Table 78 Chinese Breast Cancer Intervention Market Comparison, by Service Type, 2016
Table 79 Breast Cancer Targeting Drug Permission in China, 2016
Table 80 Chinese Cancer Intervention Market for Other Cancers, by Service Type, Through 2022
Table 81 Thyroid Cancer Targeting Drug Permission in China, 2016
Table 82 Leukemia Cancer Targeting Drug Permission in China, 2016
Table 83 Pancreatic Cancer Targeting Drug Permission in China, 2016
Table 84 Lymphoma Targeting Drug Permission in China, 2016
Table 85 Ovarian, Cervical and Fallopian Tube Cancer Targeting Drug Permission in China, 2016
Table 86 Melanoma Targeting Drug Permission in China, 2016
Table 87 Chinese Cancer Intervention Market, by Region, Through 2022
Table 88 East China Cancer Intervention Market, by Province, Through 2022
Table 89 East China Cancer Intervention Market per Capita, by Province, in 2016
Table 90 Middle China Cancer Intervention Market, by Province, Through 2022
Table 91 Middle China Cancer Intervention Market per Capita, by Province, in 2016
Table 92 North China Cancer Intervention Market, by Province, Through 2022
Table 93 North China Cancer Intervention Market per Capita, by Province, in 2016
Table 94 Southwest China Cancer Intervention Market, by Province, Through 2022
Table 95 Southwest China Cancer Intervention Market per Capita, by Province, in 2016
Table 96 Northwest China Cancer Intervention Market, by Province, Through 2022
Table 97 Northwest China Cancer Intervention Market per Capita, by Province, in 2016
Table 98 Northeast China Cancer Intervention Market, by Province, Through 2022
Table 99 Northeast China Cancer Intervention Market per Capita, by Province, in 2016
Table 100 South China Cancer Intervention Market, by Province, Through 2022
Table 101 South China Cancer Intervention Market per Capita, by Province, in 2016
Table 102 Lung Cancer Targeting Drug Permission in China, 2016
Table 103 Astellas Sales in China, Through 2022
Table 104 AstraZeneca's Sales in China, Through 2022
Table 105 Bayer Drug Sales in China, Through 2022
Table 106 Bristol-Myers Squibb Cancer Drug Sales in China, Through 2022
Table 107 Chiatai Tianqing Cancer Drug Sales in China, Through 2022
Table 108 Fsens Cancer Drug Sales in China, Through 2022
Table 109 Yibai Cancer Drug Sales in China, Through 2022
Table 110 Hahsoh Cancer Drug Sales in China, Through 2022
Table 111 Hengrui Cancer Drug Sales in China, Through 2022
Table 112 Johnson & Johnson Drug Sales in China, Through 2022
Table 113 Lunan Drug Sales in China, Through 2022
Table 114 Luye Drug Sales in China, Through 2022
Table 115 MSD Drug Sales in China, Through 2022
Table 116 Novartis Drug Sales in China, Through 2022
Table 117 Pfizer Drug Sales in China, Through 2022
Table 118 Qilu Drug Sales in China, Through 2022
Table 119 Roche Drug Sales in China, Through 2022
Table 120 Sanofi Drug Sales in China, Through 2022
Table 121 Kanglaite Drug Sales in China, Through 2022
Table 122 Glossary/Abbreviations in this Report

List Of Figures

LIST OF FIGURES

Summary Figure Chinese Market for Cancer Intervention, by Service Type, 2016-2022
Figure 1 Drug Supply Chain in China
Figure 2 Chinese Market for Cancer Intervention, by Major Segments, 2016-2022
Figure 3 Chinese Market for Cancer Intervention, by Major Type, 2016-2022
Figure 4 Chinese Paclitaxel Market Share, by Product, 2016
Figure 5 Chinese Pemetrexed Disodium Market Share, by Producer, 2016
Figure 6 Chinese Docetaxel Market Share, by Producer, 2016
Figure 7 Chinese Tegafur/Gimeracil/Oteracil Market Share, by Producer, 2016
Figure 8 Chinese Oxaliplatin Market, by Producer, 2016
Figure 9 Chinese Imatinib Market Share, by Producer, 2016
Figure 10 Chinese Capecitabine Market Share, by Producer, 2016
Figure 11 Chinese Thymopentin Market Share, by Producer, 2016
Figure 12 Chinese Tacrolimus Market Share, by Producer, 2016
Figure 13 Chinese Cancer Intervention Market, by Region, 2016-2022